SA520411726B1 - مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه - Google Patents

مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه

Info

Publication number
SA520411726B1
SA520411726B1 SA520411726A SA520411726A SA520411726B1 SA 520411726 B1 SA520411726 B1 SA 520411726B1 SA 520411726 A SA520411726 A SA 520411726A SA 520411726 A SA520411726 A SA 520411726A SA 520411726 B1 SA520411726 B1 SA 520411726B1
Authority
SA
Saudi Arabia
Prior art keywords
pharmaceutical composition
same
phenylpyridine derivative
novel phenylpyridine
novel
Prior art date
Application number
SA520411726A
Other languages
English (en)
Inventor
- سيوك بارك جون
بارك جونج-إون
بانج كيوك-تشان
كيم ول-يونج
Original Assignee
.دايوونج فارماسوتيكال كو.، ليمتد
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by .دايوونج فارماسوتيكال كو.، ليمتد filed Critical .دايوونج فارماسوتيكال كو.، ليمتد
Publication of SA520411726B1 publication Critical patent/SA520411726B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

يتعلق الكشف الحالي بمشتق فينيل بيريدين جديد novel phenylpyridine derivative الذي تمثله الصيغة الكيميائية 1 وتركيبة صيدلانية تشتمل عليه، ويمكن استخدام المركب وفقاً للكشف الحالي على نحو مفيد للوقاية من أو علاج أمراض المناعة الذاتية treatment of autoimmune diseases أو أورام السرطان cancers.
SA520411726A 2017-10-11 2020-04-07 مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه SA520411726B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020170131349A KR102613433B1 (ko) 2017-10-11 2017-10-11 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물

Publications (1)

Publication Number Publication Date
SA520411726B1 true SA520411726B1 (ar) 2022-06-27

Family

ID=66101569

Family Applications (1)

Application Number Title Priority Date Filing Date
SA520411726A SA520411726B1 (ar) 2017-10-11 2020-04-07 مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه

Country Status (23)

Country Link
US (1) US11149019B2 (ar)
EP (1) EP3696176B1 (ar)
JP (1) JP6876873B2 (ar)
KR (2) KR102613433B1 (ar)
CN (1) CN111212833B (ar)
AU (1) AU2018349293B2 (ar)
BR (1) BR112020007177A2 (ar)
CA (1) CA3076667C (ar)
CL (1) CL2020000940A1 (ar)
CO (1) CO2020004319A2 (ar)
DO (1) DOP2020000077A (ar)
EC (1) ECSP20021379A (ar)
ES (1) ES2915583T3 (ar)
MA (1) MA50368A (ar)
MX (1) MX2020003616A (ar)
MY (1) MY194695A (ar)
NZ (1) NZ763263A (ar)
PH (1) PH12020550252A1 (ar)
RU (1) RU2748945C1 (ar)
SA (1) SA520411726B1 (ar)
SG (1) SG11202002422WA (ar)
TN (1) TN2020000050A1 (ar)
WO (1) WO2019074275A1 (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019072942A1 (en) 2017-10-11 2019-04-18 F. Hoffmann-La Roche Ag BICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF KINASE RIP1
WO2021172922A1 (ko) * 2020-02-26 2021-09-02 주식회사 대웅제약 헤테로사이클릭아민 유도체의 제조 방법
KR102531088B1 (ko) * 2020-02-26 2023-05-10 주식회사 대웅제약 헤테로사이클릭아민 유도체의 제조 방법

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2257461T3 (es) 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
US20060030016A1 (en) 2003-12-05 2006-02-09 Graham Cheetham Crystal structure of interleukin-2 tyrosine kinase (ITK) and binding pockets thereof
WO2005066335A1 (en) 2003-12-30 2005-07-21 Boehringer Ingelheim Pharmaceuticals, Inc. Crystal structure of the interleukin-2-inducible cell kinase (itk) kinase domain
US7429605B2 (en) 2005-08-04 2008-09-30 Hoffmann-La Roche Inc. Phenylpyridine derivatives
TW200811134A (en) * 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
PE20080839A1 (es) 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
KR101315610B1 (ko) 2006-09-22 2013-10-10 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제 억제제
CA2683152A1 (en) 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
ES2660418T3 (es) * 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
WO2010144647A1 (en) * 2009-06-12 2010-12-16 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
NZ627709A (en) * 2010-06-23 2014-12-24 Hanmi Science Co Ltd Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
EP2588471A1 (en) * 2010-06-30 2013-05-08 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
WO2012035055A1 (en) * 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EP2890691B1 (en) 2012-08-31 2018-04-25 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
CN104822663B (zh) * 2012-10-04 2017-03-08 犹他大学研究基金会 作为酪氨酸受体激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
JP6559132B2 (ja) 2013-08-23 2019-08-14 ニューファーマ， インコーポレイテッド ある特定の化学的実体、組成物および方法
DK3060550T3 (da) * 2013-10-21 2019-07-22 Merck Patent Gmbh Heteroarylforbindelser som btk-inhibitorer og anvendelser deraf
WO2015151006A1 (en) * 2014-03-29 2015-10-08 Lupin Limited Substituted purine compounds as btk inhibitors
WO2015157556A1 (en) 2014-04-09 2015-10-15 Kadmon Corporation, Llc Treatment of gvhd
US9717745B2 (en) * 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases

Also Published As

Publication number Publication date
KR102613433B1 (ko) 2023-12-13
AU2018349293B2 (en) 2020-10-08
MX2020003616A (es) 2020-07-28
EP3696176A4 (en) 2021-03-17
AU2018349293A1 (en) 2020-04-23
ES2915583T3 (es) 2022-06-23
NZ763263A (en) 2023-02-24
JP2020536093A (ja) 2020-12-10
TN2020000050A1 (en) 2021-10-04
JP6876873B2 (ja) 2021-05-26
US11149019B2 (en) 2021-10-19
BR112020007177A2 (pt) 2020-09-24
KR20190040773A (ko) 2019-04-19
DOP2020000077A (es) 2020-08-15
CN111212833A (zh) 2020-05-29
CL2020000940A1 (es) 2020-09-04
EP3696176A1 (en) 2020-08-19
CN111212833B (zh) 2022-09-06
CO2020004319A2 (es) 2020-04-24
CA3076667A1 (en) 2019-04-18
US20200223821A1 (en) 2020-07-16
WO2019074275A1 (ko) 2019-04-18
CA3076667C (en) 2022-06-21
RU2748945C1 (ru) 2021-06-02
KR20220066012A (ko) 2022-05-23
ECSP20021379A (es) 2020-05-29
PH12020550252A1 (en) 2021-02-22
MY194695A (en) 2022-12-15
SG11202002422WA (en) 2020-04-29
MA50368A (fr) 2021-03-17
EP3696176B1 (en) 2022-05-04

Similar Documents

Publication Publication Date Title
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
PH12019500480A1 (en) Pyridine compound
MX2018005019A (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
GEP20207126B (en) New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them
MY196572A (en) Amino-Methyl Piperidine Derivative as Kinase Inhibitor
GEP20186887B (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
SA520411726B1 (ar) مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه
PH12019500196A1 (en) Compounds and compositions and uses thereof
MX2019013419A (es) Compuestos plaguicidas biciclicos.
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
MX2020006434A (es) Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
PH12021550329A1 (en) Novel heterocyclic amine derivative and pharmaceutical composition comprising same
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
GEP20186893B (en) Pyrazines modulators of gpr6
MX2020006436A (es) Compuestos inhibidores del blanco mecanistico de rapamicina (mtor).
SG11201803867TA (en) Sodium channel blocker
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
MX2018015269A (es) Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos.
WO2018080215A8 (en) 3-AMINO ALKYLATED INDOLE DERIVATIVE, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF
NZ748746A (en) Pyrazolopyrimidine derivatives as kinase inhibitor